Is ATYR or GLSI more profitable?

aTyr Pharma's return on equity of -100.14% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -100.14% -73.55% Greenwich LifeSciences N/A -941.15% -368.53%

Does the media refer more to ATYR or GLSI?

In the previous week, Greenwich LifeSciences had 4 more articles in the media than aTyr Pharma. MarketBeat recorded 5 mentions for Greenwich LifeSciences and 1 mentions for aTyr Pharma. Greenwich LifeSciences' average media sentiment score of 1.49 beat aTyr Pharma's score of 0.00 indicating that Greenwich LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Greenwich LifeSciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NERV or ATYR more profitable?

Minerva Neurosciences' return on equity of 0.00% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -32.63% aTyr Pharma N/A -100.14% -73.55%

Does the media favor NERV or ATYR?

In the previous week, Minerva Neurosciences had 2 more articles in the media than aTyr Pharma. MarketBeat recorded 3 mentions for Minerva Neurosciences and 1 mentions for aTyr Pharma. Minerva Neurosciences' average media sentiment score of 1.75 beat aTyr Pharma's score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive aTyr Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ATYR or DTIL?

In the previous week, Precision BioSciences had 7 more articles in the media than aTyr Pharma. MarketBeat recorded 8 mentions for Precision BioSciences and 1 mentions for aTyr Pharma. Precision BioSciences' average media sentiment score of 0.42 beat aTyr Pharma's score of 0.00 indicating that Precision BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precision BioSciences 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor VYGR or ATYR?

In the previous week, Voyager Therapeutics had 2 more articles in the media than aTyr Pharma. MarketBeat recorded 3 mentions for Voyager Therapeutics and 1 mentions for aTyr Pharma. Voyager Therapeutics' average media sentiment score of 0.00 equaled aTyr Pharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral aTyr Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is WHWK or ATYR more profitable?

Whitehawk Therapeutics' return on equity of -79.63% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics N/A -79.63% -74.01% aTyr Pharma N/A -100.14% -73.55%

Does the media refer more to WHWK or ATYR?

In the previous week, Whitehawk Therapeutics had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 2 mentions for Whitehawk Therapeutics and 1 mentions for aTyr Pharma. Whitehawk Therapeutics' average media sentiment score of 0.84 beat aTyr Pharma's score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive aTyr Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

aTyr Pharma (ATYR) Competitors

$0.52 +0.03 (+6.50%)

As of 02:56 PM Eastern

Compare

ATYR vs. GLSI, NERV, DTIL, VYGR, and WHWK

Should you buy aTyr Pharma stock or one of its competitors? MarketBeat compares aTyr Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with aTyr Pharma include Greenwich LifeSciences (GLSI), Minerva Neurosciences (NERV), Precision BioSciences (DTIL), Voyager Therapeutics (VYGR), and Whitehawk Therapeutics (WHWK).

How does aTyr Pharma compare to Greenwich LifeSciences?

aTyr Pharma (NASDAQ:ATYR) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

aTyr Pharma's return on equity of -100.14% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-100.14%	-73.55%
Greenwich LifeSciences	N/A	-941.15%	-368.53%

aTyr Pharma has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

In the previous week, Greenwich LifeSciences had 4 more articles in the media than aTyr Pharma. MarketBeat recorded 5 mentions for Greenwich LifeSciences and 1 mentions for aTyr Pharma. Greenwich LifeSciences' average media sentiment score of 1.49 beat aTyr Pharma's score of 0.00 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Greenwich LifeSciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Greenwich LifeSciences has lower revenue, but higher earnings than aTyr Pharma. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	272.99	-$74.12M	-$0.73	N/A
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A

aTyr Pharma presently has a consensus price target of $17.00, indicating a potential upside of 3,113.61%. Greenwich LifeSciences has a consensus price target of $57.00, indicating a potential upside of 311.40%. Given aTyr Pharma's higher possible upside, equities analysts plainly believe aTyr Pharma is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 5.8% of aTyr Pharma shares are owned by company insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

aTyr Pharma beats Greenwich LifeSciences on 8 of the 15 factors compared between the two stocks.

How does aTyr Pharma compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

Minerva Neurosciences' return on equity of 0.00% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-32.63%
aTyr Pharma	N/A	-100.14%	-73.55%

aTyr Pharma has higher revenue and earnings than Minerva Neurosciences. aTyr Pharma is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A
aTyr Pharma	$190K	272.99	-$74.12M	-$0.73	N/A

Minerva Neurosciences has a beta of -0.16, suggesting that its stock price is 116% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Minerva Neurosciences presently has a consensus target price of $10.50, indicating a potential upside of 157.10%. aTyr Pharma has a consensus target price of $17.00, indicating a potential upside of 3,113.61%. Given aTyr Pharma's stronger consensus rating and higher possible upside, analysts clearly believe aTyr Pharma is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

In the previous week, Minerva Neurosciences had 2 more articles in the media than aTyr Pharma. MarketBeat recorded 3 mentions for Minerva Neurosciences and 1 mentions for aTyr Pharma. Minerva Neurosciences' average media sentiment score of 1.75 beat aTyr Pharma's score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by company insiders. Comparatively, 5.8% of aTyr Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

aTyr Pharma beats Minerva Neurosciences on 9 of the 14 factors compared between the two stocks.

How does aTyr Pharma compare to Precision BioSciences?

aTyr Pharma (NASDAQ:ATYR) and Precision BioSciences (NASDAQ:DTIL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 5.8% of aTyr Pharma shares are owned by company insiders. Comparatively, 2.7% of Precision BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Precision BioSciences had 7 more articles in the media than aTyr Pharma. MarketBeat recorded 8 mentions for Precision BioSciences and 1 mentions for aTyr Pharma. Precision BioSciences' average media sentiment score of 0.42 beat aTyr Pharma's score of 0.00 indicating that Precision BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precision BioSciences	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

aTyr Pharma presently has a consensus target price of $17.00, suggesting a potential upside of 3,113.61%. Precision BioSciences has a consensus target price of $32.25, suggesting a potential upside of 345.13%. Given aTyr Pharma's higher possible upside, equities analysts clearly believe aTyr Pharma is more favorable than Precision BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

aTyr Pharma has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Precision BioSciences has higher revenue and earnings than aTyr Pharma. Precision BioSciences is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	272.99	-$74.12M	-$0.73	N/A
Precision BioSciences	$34.26M	5.46	-$45.72M	-$3.67	N/A

aTyr Pharma has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Precision BioSciences' return on equity of -85.37% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-100.14%	-73.55%
Precision BioSciences	-96.73%	-85.37%	-37.34%

Summary

Precision BioSciences beats aTyr Pharma on 9 of the 17 factors compared between the two stocks.

How does aTyr Pharma compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by company insiders. Comparatively, 5.8% of aTyr Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Voyager Therapeutics presently has a consensus target price of $16.50, indicating a potential upside of 436.59%. aTyr Pharma has a consensus target price of $17.00, indicating a potential upside of 3,113.61%. Given aTyr Pharma's higher possible upside, analysts clearly believe aTyr Pharma is more favorable than Voyager Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Voyager Therapeutics has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

In the previous week, Voyager Therapeutics had 2 more articles in the media than aTyr Pharma. MarketBeat recorded 3 mentions for Voyager Therapeutics and 1 mentions for aTyr Pharma. Voyager Therapeutics' average media sentiment score of 0.00 equaled aTyr Pharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

aTyr Pharma has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	4.60	-$119.72M	-$1.97	N/A
aTyr Pharma	$190K	272.99	-$74.12M	-$0.73	N/A

aTyr Pharma has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Voyager Therapeutics' return on equity of -55.97% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
aTyr Pharma	N/A	-100.14%	-73.55%

Summary

Voyager Therapeutics beats aTyr Pharma on 8 of the 15 factors compared between the two stocks.

How does aTyr Pharma compare to Whitehawk Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Whitehawk Therapeutics currently has a consensus target price of $8.20, indicating a potential upside of 98.55%. aTyr Pharma has a consensus target price of $17.00, indicating a potential upside of 3,113.61%. Given aTyr Pharma's higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

In the previous week, Whitehawk Therapeutics had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 2 mentions for Whitehawk Therapeutics and 1 mentions for aTyr Pharma. Whitehawk Therapeutics' average media sentiment score of 0.84 beat aTyr Pharma's score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Whitehawk Therapeutics has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

Whitehawk Therapeutics' return on equity of -79.63% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-79.63%	-74.01%
aTyr Pharma	N/A	-100.14%	-73.55%

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Comparatively, 5.8% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Whitehawk Therapeutics has higher earnings, but lower revenue than aTyr Pharma. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	N/A	N/A	-$20.60M	-$1.68	N/A
aTyr Pharma	$190K	272.99	-$74.12M	-$0.73	N/A

Summary

Whitehawk Therapeutics beats aTyr Pharma on 8 of the 15 factors compared between the two stocks.

Get aTyr Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATYR vs. The Competition

Export

Metric	aTyr Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$51.77M	$3.54B	$6.80B	$13.01B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-0.72	7.36	279.98	25.51
Price / Sales	272.99	1,272.68	649.35	116.02
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	0.77	17.18	11.15	6.35
Net Income	-$74.12M	-$12.52M	$3.48B	$347.60M
7 Day Performance	7.09%	2.48%	2.51%	3.14%
1 Month Performance	-10.72%	-5.41%	-2.78%	-2.08%
1 Year Performance	-89.46%	51.14%	64.32%	21.27%

aTyr Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATYR aTyr Pharma	3.1479 of 5 stars	$0.52 +6.5%	$17.00 +3,144.3%	-89.5%	$51.38M	$190K	N/A	53	Upcoming Earnings Gap Up
GLSI Greenwich LifeSciences	3.0876 of 5 stars	$13.44 +3.5%	$57.00 +324.1%	+22.1%	$190.52M	N/A	N/A	3	Gap Up
NERV Minerva Neurosciences	1.8832 of 5 stars	$4.20 +4.0%	$10.50 +150.0%	+106.2%	$188.22M	N/A	N/A	9	News Coverage Positive News
DTIL Precision BioSciences	2.6546 of 5 stars	$7.25 -0.5%	$32.25 +344.8%	+52.8%	$188.10M	$45.07M	N/A	200	News Coverage Positive News Upcoming Earnings Analyst Forecast Analyst Revision
VYGR Voyager Therapeutics	2.135 of 5 stars	$3.09 -0.3%	$16.50 +434.0%	+1.4%	$187.31M	$40.37M	N/A	100	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATYR) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

aTyr Pharma (ATYR) Competitors

ATYR vs. GLSI, NERV, DTIL, VYGR, and WHWK

How does aTyr Pharma compare to Greenwich LifeSciences?

Summary

How does aTyr Pharma compare to Minerva Neurosciences?

Summary

How does aTyr Pharma compare to Precision BioSciences?

Summary

How does aTyr Pharma compare to Voyager Therapeutics?

Summary

How does aTyr Pharma compare to Whitehawk Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR vs. The Competition

aTyr Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

aTyr Pharma (ATYR) Competitors

ATYR vs. GLSI, NERV, DTIL, VYGR, and WHWK

How does aTyr Pharma compare to Greenwich LifeSciences?

Is ATYR or GLSI more profitable?

Which has more risk & volatility, ATYR or GLSI?

Does the media refer more to ATYR or GLSI?

Which has preferable earnings & valuation, ATYR or GLSI?

Do analysts rate ATYR or GLSI?

Do institutionals & insiders believe in ATYR or GLSI?

Summary

How does aTyr Pharma compare to Minerva Neurosciences?

Is NERV or ATYR more profitable?

Which has preferable earnings and valuation, NERV or ATYR?

Which has more risk and volatility, NERV or ATYR?

Do analysts prefer NERV or ATYR?

Does the media favor NERV or ATYR?

Do insiders & institutionals have more ownership in NERV or ATYR?

Summary

How does aTyr Pharma compare to Precision BioSciences?

Do insiders and institutionals hold more shares of ATYR or DTIL?

Does the media prefer ATYR or DTIL?

Do analysts recommend ATYR or DTIL?

Which has more risk and volatility, ATYR or DTIL?

Which has stronger valuation and earnings, ATYR or DTIL?

Is ATYR or DTIL more profitable?

Summary

How does aTyr Pharma compare to Voyager Therapeutics?

Do insiders & institutionals believe in VYGR or ATYR?

Do analysts recommend VYGR or ATYR?

Which has more risk & volatility, VYGR or ATYR?

Does the media favor VYGR or ATYR?

Which has higher valuation and earnings, VYGR or ATYR?

Is VYGR or ATYR more profitable?

Summary

How does aTyr Pharma compare to Whitehawk Therapeutics?

Do analysts rate WHWK or ATYR?

Does the media refer more to WHWK or ATYR?

Which has more risk & volatility, WHWK or ATYR?

Is WHWK or ATYR more profitable?

Do institutionals & insiders have more ownership in WHWK or ATYR?

Which has better earnings & valuation, WHWK or ATYR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR vs. The Competition

aTyr Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools